The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Journal club

Journal club: STEP 3 and the intensive behavioural therapy floor — does this still hold?

Solved
Solved by a.finnegan_rd in post #2
Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then limitations. That order makes critique coherent.

Jump to the accepted answer →

SO
s.okonkwoTL2 Moderator17 Jul 2025#1

The question in the title: Journal club: STEP 3 and the intensive behavioural therapy floor — does this still hold? I will give what I have already checked below so nobody repeats it.

Session topic: STEP 4 (JAMA, 2021). Please read it before posting; the discussion is much better when everyone has.

The question I would like us to start with is what the trial set out to estimate, rather than what it found. Once that is on the table we can talk about whether the design could have answered it, and only then about the numbers.

Specific things I would like covered: the population and how far it generalises, how discontinuation was handled, whether the comparator was a fair one, and what the absolute rather than relative effect looks like.

I will summarise at the end and the summary will feed the relevant digest page.

44 likes 12mo
AF
a.finnegan_rdTL2Dietitian Solution26 Aug 2025#2

Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then limitations. That order makes critique coherent.

11 likes 11mo
VK
v.kirchnerTL2 Moderator24 Sep 2025#3

STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially larger than anything previously achieved pharmacologically.

3 likes 10mo

Suggested topics

TopicParticipantsRepliesViewsActivity
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Comparing STEP 2 ( Lancet , 2021) with SURMOUNT-4 ( JAMA , 2024) and…
MDAWRMJDVR+118 132 12k 15mo
Journal club: STEP 8 and the fairness of the comparator dose
Journal club: STEP 8 and the fairness of the comparator dose — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022) and finding…
ANBRCCDSO+2 6 39k 12mo
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with SURMOUNT-4 ( JAMA , 2024) and…
AKACRIGKR+103 110 8.1k 2h
Journal club: what we got wrong in an earlier session
On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before posting; the…
NAFPALVSFT+114 125 2.5k 23h
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field
Posting this under the heading it deserves: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with SCALE ( N Engl J…
CIRCBPMN+47 51 617 16mo

Related topics — sharing the tags journal club, effect size, number needed to treat

TopicParticipantsRepliesViewsActivity
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med…
CWMHRSOBRZ+43 47 19k 2d
Follow-up: Tirzepatide's shorter half-life and its one practical consequence
Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of…
JEYMPDBJTK+130 137 11k 19mo
Journal club: how we handle discontinuation in obesity trials
On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
LSCLPM 2 1.9k 12mo
Measurement error in home scales, with a worked standard deviation — a second dataset
Measurement error in home scales, with a worked standard deviation — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2…
AKKSA 2 13k 7mo
Preprint servers and what screening they do
Preprint servers and what screening they do — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
BTSRDNMRL+95 106 5.6k 4mo